3-苄基-7-溴喹唑啉-4-酮 | 832114-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3-苄基-7-溴喹唑啉-4-酮
• 英文名称: 3-benzyl-7-bromoquinazolin-4(3H)-one
• 英文别名: 3-benzyl-7-bromo-4-oxo-3,4-dihydroquinazoline；3-Benzyl-7-bromo-3H-quinazolin-4-one；3-benzyl-7-bromoquinazolin-4-one
• CAS: 832114-33-7
• 化学式: C₁₅H₁₁BrN₂O
• 分子量: 315.169
• InChiKey: UKRKRWVZZRAVKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-苄基-7-溴喹唑啉-4-酮 、 N-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)benzamide 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以71%的产率得到3-(3-Benzyl-4-oxo-3,4-dihydro-quinazolin-7-yl)-N-cyclopropyl-4-methyl-benzamide
  参考文献：
  名称：

  P-38 kinase inhibitors

  摘要：

  提供了用于调节p38激酶活性的化合物和组合物，包括p38α和p38β激酶。还提供了用于治疗、预防或缓解p38激酶介导的疾病或紊乱的一种或多种症状的方法。

  公开号：

  US20050020590A1
• 作为产物：
  描述：

  2-氨基-4-溴苯甲酸甲酯 在 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 3-苄基-7-溴喹唑啉-4-酮
  参考文献：
  名称：

  角噻唑并[5,4- f ]和[4,5- h ]喹唑啉的新型合成，其线性噻唑并[4,5- g ]和[5,4- g ]喹唑啉类似物的制备

  摘要：

  9-氧代8,9-二氢噻唑[5,4- f ]喹唑啉-2-腈（1）或6-氧代6,7-二氢噻唑[4,5 - h ]喹唑啉-2-腈（2）的合成）进行了重新研究，目的是改变与喹唑啉4-one部分相连的噻唑环的位置，以便合成两个新颖的线性三环式8-氧代-7,8-二氢噻唑并[4,5- g ]喹唑啉- 2-甲腈（3）和8-氧代7,8-二氢噻唑并[5,4 - g ]喹唑啉-2-甲腈（4）。本文描述的途径为获得有效的生物活性杂环化合物文库提供了各种替代和转化途径。

  DOI：

  10.1016/j.tet.2013.02.066

文献信息

• Dairyl-substituted five-membered heterocycle derivative
  申请人：Hirata Yukari

  公开号：US20070173507A1

  公开（公告）日：2007-07-26

  The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了由公式（I）所表示的化合物：（I）或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表公式（II-1）：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，A环代表苯基等，具有mGluR1抑制作用，适用于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性脑缺血发作、精神疾病如精神分裂症、焦虑、药物依赖、帕金森病或胃肠道疾病。
• DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE
  申请人：Hirata Yukari

  公开号：US20110160208A1

  公开（公告）日：2011-06-30

  The present invention provides the compounds represented by formula (I): or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being useful for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了以下式子(I)所代表的化合物或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表式子(II-1)：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，环A代表苯基等，具有mGluR1抑制作用，并且对于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性缺血性发作、精神障碍如精神分裂症、焦虑、药物依赖、帕金森病或胃肠疾病有用。
• P-38 Kinase Inhibitors
  申请人：Lang Hengyuan

  公开号：US20100234404A1

  公开（公告）日：2010-09-16

  Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α, and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.

  本文提供了调节p38激酶活性的化合物和组合物，包括p38α和p38β激酶。还提供了治疗、预防或改善p38激酶介导的疾病或疾病症状的方法。
• Diaryl-substituted five-membered heterocycle derivative
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07902369B2

  公开（公告）日：2011-03-08

  The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X1 represents oxygen atoms and the like, X2 represents nitrogen atoms and the like, X3 represents nitrogen atoms and the like, X4 represents nitrogen atoms and the like, R1 represents formula (II-1): wherein X5 represents sulfur atoms and the like, A1 represents carbon atoms and the like, A2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了由式(I)表示的化合物或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1表示公式(II-1)：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，A环表示苯基等，具有mGluR1抑制作用，并且对于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑疾病如脑梗塞或暂时性缺血性发作、精神障碍如精神分裂症、焦虑、药物依赖、帕金森病或胃肠疾病具有用处。
• Visible light-induced cascade <i>N</i>-alkylation/amidation reaction of quinazolin-4(3<i>H</i>)-ones and related N-heterocycles
  作者：Jiexiong Mai、Ziwei Huang、Shaohuan Lv、Quan Chen、Rongrong Chen、Feng Xie、Jun Wang、Bin Li

  DOI：10.1039/d2ob02226e

  日期：——

  An efficient and visible light-promoted cascade N-alkylation/amidation of quinazolin-4(3H)-ones with benzyl halides and allyl halides has been described for the first time to provide a convenient access to quinazoline-2,4(1H,3H)-diones. This cascade N-alkylation/amidation reaction shows good functional group tolerance and could also be applied to N-heterocycles such as benzo[d]thiazoles, benzo[d]imidazoles

  首次描述了喹唑啉-4(3 H )-与苄基卤化物和烯丙基卤化物的有效且可见光促进的级联N-烷基化/酰胺化，以提供对喹唑啉-2,4(1 H)的便捷途径,3 H )-二酮。这种级联N-烷基化/酰胺化反应显示出良好的官能团耐受性，也可应用于 N-杂环，如苯并 [ d ] 噻唑、苯并 [ d ] 咪唑和喹唑啉。对照实验表明，K 2 CO 3在这种转化中起着重要作用。